The Abbott Split Up: Who Wins?
After implementing a workforce reduction of 1,900 U.S. employees in January, Abbott Laboratories Inc. in recent months had re-organized its diversified company into three units – proprietary pharmaceuticals, durable growth products and innovation-driven devices. Its latest announcement cements that change: Abbott will divide into a diversified medical products company, to retain the Abbott name, and a research-based pharmaceuticals company, which will take a new, to-be-determined name.
You may also be interested in...
Ikaria’s Hybrid Business Model Taps Big Pharma Trends
Although Ikaria focuses on a highly specialized segment of the hospital market, its integrated business model offers insights into continuum of care strategies that pharma companies are evaluating in a reimbursement-focused world. The company’s promising strategy could get a boost from key trial read-outs as soon as late 2012.
Abbott Vaults Into Oral HCV Race; Near-Term Focus Is Humira, Split
The pharma did not offer much detail on plans to split into two publicly traded companies during its quarterly call, but did shed some light on its HCV pipeline one day ahead of EASL.
Abbott Spin-Off AbbVie To Remain Close To Its Roots
Abbott announces that its research-based pharmaceutical division will be called AbbVie once it splits off at the end of the year.